Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Announcement on the Approval for MAA of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product “AMCHEPRY” in Japan
Presentation Material (Boost 2028 - Accelerating Strong Sumitomo Pharma -)
Sumitomo Pharma Announces Boost 2028 - Accelerating Strong Sumitomo Pharma -
Announcement of Filing of Shelf Registration Statement for Issuance of New Shares
Sumitomo Pharma Announces Revisions to Its Financial Forecasts
Sumitomo Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 11%, Exceeded Record Profit Forecast
Publication of Materials from the R&D Meeting for Analysts, Investors, and Media
Regarding the Scheduled Review in Japan of the Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells (AMCHEPRY)
Presentation Material (Conference on Q3 FY2025 Financial Results)
Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 [IFRS]
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2026
Sumitomo Pharma, Apr-Dec (Cumulative 3Q) Net Income Increases by 5.1 times, Oct-Dec Net Income Decreases by 84%
Sumitomo Pharma Selected as “Best Website” for the Third Consecutive Year in Both All Markets and Pharmaceuticals Sector Categories
Sumitomo Pharma Selected as Highest Rating A-List Company by CDP for Two Consecutive Years in the Category of Climate Change in the CDP 2025
Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the ASH 2025
Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2026
Sumitomo Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 2.3 times, Highest in Four Terms
Sumitomo Pharma Announces Variances Between Its Financial Forecasts for the Half-Year Ended September 30, 2025, and Revisions to Financial Forecasts
(Progress of Disclosure Matters) Confirmation of Gain on Sales of Shares of Subsidiaries in connection with the Company Split of Asian Business
Presentation Material (Conference on Q2 FY2025 Financial Results)